Core Viewpoint - New Ganjing (873167) reported a revenue of 154 million yuan and a net profit of 22.41 million yuan for the year 2024, with a proposed cash dividend of 1 yuan per 10 shares, totaling approximately 7.0861 million yuan [1] Group 1: Financial Performance - The company achieved a revenue of 154 million yuan and a net profit attributable to shareholders of 22.41 million yuan, resulting in an earnings per share of 0.32 yuan [1] - The proposed cash dividend is 1 yuan for every 10 shares, amounting to around 7.0861 million yuan [1] Group 2: Business Strategy and Development - Since its establishment, the company has focused on consolidating its glucose acid salt raw material business while extending into formulation products, aiming to transition from a raw material-based pharmaceutical company to a comprehensive brand pharmaceutical enterprise [1] - In 2024, the revenue from formulation drugs and traditional Chinese medicine reached 73.8462 million yuan, accounting for 48% of the total revenue [1] Group 3: Research and Development - The company emphasizes R&D, with R&D expenditure exceeding 5% of revenue, focusing on innovation and optimization of existing raw materials and formulation products [2] - Over 20 new products, processes, and categories are under development, including research on high-efficiency enzyme methods for calcium gluconate preparation, which has entered the pilot test stage [2] - The company plans to enhance brand recognition and product structure while introducing high-margin trade products to complement its offerings [2]
新赣江持续完善健康产业生态链 2024年实现净利2241万元